- Twist Biosciences ( NASDAQ: TWST ) has entered into a collaboration with DNAnexus to develop next-generation sequencing-based diagnostic tests .
- The agreement allows Twist ( TWST ) customers to use the company's NGS Methylation Detection System and Unique Molecular Identifier Adapter System with the DNAnexus platform to simplify data analysis after sequencing.
- The DNAnexus platform provides a cloud environment for diagnostic development and the production cycle from R&D through to deployment of the validated test.
- Check out Seeking Alpha contributor Bret Jensen's take on Twist ( TWST ).
For further details see:
Twist Biosciences to work with DNAnexus on sequencing-based diagnostic tests